Pulmonary Embolism

Overview

Pulmonary embolism is the sudden blockage of one or more of the arteries supplying blood to the lungs. In the vast majority of cases, the blockage is caused by a blood clot that has formed in the deep veins of the leg or pelvis, broken free, traveled through the venous circulation, and lodged in a pulmonary artery. This deep vein clot — known as deep vein thrombosis — and the subsequent pulmonary embolism are closely linked conditions, often considered part of the same disease process called venous thromboembolism.

When a clot obstructs a pulmonary artery, blood flow to that part of the lung is halted or severely reduced. The affected lung tissue can no longer participate in gas exchange, and the heart — now forced to pump against greatly increased resistance — is placed under sudden and significant strain. Depending on the size of the clot and the person's underlying health, pulmonary embolism can range from mild breathlessness to sudden cardiac arrest and death.

Pulmonary embolism is a life-threatening medical emergency and remains one of the leading causes of preventable in-hospital death worldwide. Yet with rapid diagnosis and appropriate treatment, the risk of dying from it can be substantially reduced. The challenge is that its symptoms overlap considerably with those of many other conditions, and some cases produce only minimal warning signs.

Risk rises sharply in specific circumstances — prolonged immobility, the postoperative period, active cancer, pregnancy, and inherited clotting disorders among them. Recognizing these risk situations and seeking medical attention the moment symptoms appear can make a decisive difference.

Symptoms

The symptoms of pulmonary embolism are both variable and non-specific, which is one reason it is frequently missed or diagnosed late. In some patients the onset is sudden and dramatic; in others symptoms develop insidiously over hours or days. Small clots may cause almost nothing, while a large or multiple simultaneous clots can produce a life-threatening collapse within minutes.

Pulmonary embolism symptoms include the following:

• Sudden shortness of breath. This is the most common and most characteristic symptom. Breathlessness that begins abruptly without physical exertion — particularly in someone who had no prior breathing difficulty — is a strong warning sign. It may start mild and only noticeable with activity, but can worsen rapidly.
• Chest pain. The pain is typically sharp and stabbing, and worsens with deep breathing, coughing, or movement. It can mimic a heart attack, but in pulmonary embolism the pain is usually breathing-related and localized to the affected part of the lung. When the pleura (the lung lining) is involved, the pain can be particularly severe.
• Cough. A dry cough is common. Coughing up blood-streaked or bloody sputum — known as hemoptysis — may occur when pulmonary infarction (death of lung tissue) develops and is an important warning sign.
• Palpitations and rapid heart rate. The heart accelerates as it attempts to compensate for falling oxygen levels and increased afterload. Palpitations and a rapid pulse are frequent accompanying features. In severe cases, arrhythmias may develop.
• Dizziness and fainting. A large clot obstructing a major pulmonary artery can acutely impair the heart's pumping ability, reducing blood flow to the brain and causing lightheadedness, sudden weakness, or syncope. Fainting is a significant symptom of massive pulmonary embolism.
• Sweating and pallor. Cold sweating and pale skin reflect the body's physiological stress response. The lips and fingertips may take on a bluish tinge — called cyanosis — indicating serious oxygen depletion.
• Leg swelling, warmth, redness, and pain. These are the signs of the deep vein thrombosis from which most pulmonary emboli originate. They typically affect one leg — particularly the calf — but are absent in roughly half of deep vein thrombosis cases.

Taken individually, each of these symptoms can point to many other conditions. However, the combination of sudden breathlessness, chest pain, and palpitations — especially in someone with known risk factors — demands urgent evaluation for pulmonary embolism without delay.

When to See a Doctor

Pulmonary embolism demands urgent medical attention. The speed with which treatment is started directly determines both survival and long-term outcomes.

Call emergency services immediately or go directly to the nearest emergency department if:

• You develop sudden, unexplained shortness of breath
• You have chest pain that worsens with deep breathing or coughing
• You are coughing up blood-streaked sputum
• You have breathlessness accompanied by palpitations, dizziness, or a feeling that you are about to faint
• Your lips or fingertips are turning blue
• You have recently had surgery, been immobile for an extended period, or are receiving cancer treatment and any of the above symptoms develop

Seek prompt medical evaluation without delay if:

• One leg has developed unexplained swelling, warmth, or aching — these may indicate deep vein thrombosis
• Breathlessness or leg complaints have started after a long journey or a period of prolonged sitting
• You have a personal history of deep vein thrombosis or pulmonary embolism and similar symptoms have returned

Waiting to see whether symptoms resolve on their own is dangerous with this condition. In pulmonary embolism, the speed of diagnosis and treatment has a direct bearing on whether complications develop and whether they are survivable.

Causes

The overwhelming majority of pulmonary emboli originate from deep vein thrombosis — a blood clot in the deep veins of the legs or pelvis. The clot detaches, passes through the right side of the heart, and reaches the pulmonary arteries. Less commonly, clots arise from the deep arm veins, the heart chambers, or around intravascular medical devices.

Blood clot formation is understood through the framework of Virchow's triad — the three conditions that favor clotting: slowed blood flow, damage to the vessel wall, and a hypercoagulable state (an increased tendency of the blood to clot). When one or more of these conditions is present, the risk of thrombosis rises substantially.

The main causes and predisposing conditions for pulmonary embolism include the following:

• Prolonged immobility. Long flights or car journeys, extended bed rest, and paralysis all slow venous blood flow in the legs, allowing clot formation. Journeys lasting more than 4 hours carry meaningful risk.
• Surgery and trauma. Major surgery — particularly orthopedic, abdominal, and gynecological procedures — both damages vessel walls and forces periods of postoperative immobility. Hip and knee replacement surgeries carry some of the highest procedural risks.
• Cancer. Many cancers — particularly those of the pancreas, lung, colon, and ovary — activate the clotting system and significantly elevate thrombosis risk. Chemotherapy adds further risk. Pulmonary embolism is a common and prognostically important complication in cancer patients.
• Pregnancy and the postpartum period. During pregnancy, blood volume rises, coagulation factors increase, and the growing uterus compresses the major pelvic veins, impairing venous return. The first six weeks after delivery also carry elevated risk.
• Hormonal therapies. Estrogen-containing oral contraceptives and hormone replacement therapy increase coagulability. The risk increases dramatically when combined with smoking.
• Inherited clotting disorders. Factor V Leiden mutation, prothrombin gene mutation, protein C and S deficiency, and antithrombin deficiency are heritable thrombophilias that permanently elevate clotting tendency. Pulmonary embolism at a young age, or a strong family history of thrombosis, should prompt consideration of these conditions.
• Acquired clotting disorders. Antiphospholipid syndrome — an autoimmune condition characterized by recurrent thrombosis — is a potent risk factor for pulmonary embolism.
• Heart failure and atrial fibrillation. Heart failure slows circulation and promotes clot formation. Atrial fibrillation can generate intracardiac clots that break off and reach the pulmonary circulation.
• Obesity. Excess body weight impairs venous return from the legs and creates a pro-inflammatory, hypercoagulable environment.
• Intravascular catheters and implanted devices. Central venous catheters, pacemaker leads, and similar devices can irritate vessel walls and act as a nidus for clot formation.

Risk Factors

Some risk factors for pulmonary embolism are temporary and preventable; others are permanent or constitutional.

• Prior deep vein thrombosis or pulmonary embolism. This group has the highest recurrence risk, particularly if an underlying permanent risk factor such as thrombophilia is present.
• Advanced age. Risk increases markedly after age 60, driven by a combination of vascular changes, reduced mobility, and accumulating chronic conditions.
• Prolonged immobility. Whether from long travel, bed rest, or neurological impairment, reduced muscle pump activity in the legs significantly impairs venous return.
• Major surgery. Orthopedic and abdominal procedures carry particularly high risk. Prophylactic anticoagulation is therefore a routine part of postoperative care after these procedures.
• Active cancer. Cancer both activates the coagulation system and introduces additional risk factors through chemotherapy and central line use.
• Pregnancy and the postpartum period. Risk is 4 to 5 times higher during pregnancy than in the non-pregnant state and remains elevated for several weeks after delivery.
• Obesity. A body mass index above 30 approximately doubles the risk of pulmonary embolism.
• Smoking. Tobacco use damages vessel walls and promotes a hypercoagulable state. When combined with estrogen-containing medications, the risk multiplies substantially.
• Inherited thrombophilia. Factor V Leiden and other hereditary clotting disorders are important risk factors. Unexplained thrombosis in a young person or a strong family history warrants investigation.

Diagnosis

Diagnosing pulmonary embolism can be challenging, as its symptoms are non-specific and overlap with many other conditions. Diagnosis relies on combining clinical assessment, laboratory testing, and imaging in a structured approach.

Diagnostic methods include the following:

• Clinical probability assessment. Structured scoring tools such as the Wells score and the Geneva score use symptoms, risk factors, and examination findings to classify the likelihood of pulmonary embolism as low, intermediate, or high. This classification guides how subsequent testing is used.
• D-dimer test. D-dimer is a breakdown product of blood clots, and its blood level is measured as a screening test. In patients with low clinical probability, a negative D-dimer result effectively rules out pulmonary embolism and avoids unnecessary imaging. However, D-dimer is not specific — it is elevated in infection, pregnancy, surgery, and many other conditions — so an elevated result alone cannot confirm the diagnosis. Its value lies in ruling out rather than ruling in.
• CT pulmonary angiography (CTPA). This is the gold-standard imaging test for pulmonary embolism today. Contrast dye injected into a vein allows detailed visualization of the pulmonary arteries; clots are identified directly, their location and size are defined precisely. Its speed and high diagnostic accuracy make it the first-choice modality in emergency evaluation.
• Ventilation-perfusion (V/Q) scintigraphy. Used when CTPA is contraindicated — in patients with kidney failure, contrast allergy, or during pregnancy. It compares lung ventilation with blood perfusion to detect areas of mismatch consistent with pulmonary embolism.
• Echocardiography. Evaluates right heart strain and dysfunction, which occur when a large clot obstructs the pulmonary circulation. Right ventricular dilation and impaired function detected on echocardiography are signs of a hemodynamically significant embolism. In critically ill patients, the clot may be directly visible in the heart or main pulmonary artery. Echocardiography also guides early treatment decisions and provides important prognostic information.
• Leg ultrasonography. Used to identify deep vein thrombosis in the leg veins. This is helpful when CTPA is not possible or as supportive evidence for the diagnosis.
• Troponin and BNP measurements. These biomarkers reflect myocardial injury and cardiac strain respectively. Elevated troponin and BNP indicate a more severe pulmonary embolism and may signal the need for more aggressive treatment.
• Arterial blood gas analysis. Measures oxygen and carbon dioxide levels. Low oxygen and respiratory alkalosis are typical findings in pulmonary embolism, though neither is specific to the diagnosis.

Treatment

Treatment of pulmonary embolism aims to neutralize the existing clot, prevent new clot formation, and support cardiovascular function while the body's own clot-dissolving mechanisms work. The choice of treatment depends on the severity of the embolism, the patient's overall condition, and the risk of bleeding.

Treatment options include the following:

• Anticoagulation (blood thinners). This is the cornerstone of treatment. Low molecular weight heparin, unfractionated heparin, rivaroxaban, apixaban, dabigatran, and warfarin all belong to this group. Anticoagulants stop new clot formation and prevent existing clots from growing, allowing the body's own fibrinolytic system to gradually dissolve the clot over time. Treatment typically lasts at least three months; depending on the underlying risk factor, it may continue longer or be lifelong.
• Thrombolytic therapy (clot-dissolving drugs). Agents such as alteplase rapidly dissolve clots and restore pulmonary artery patency within hours. They are reserved for life-threatening massive pulmonary embolism — particularly when accompanied by hypotension, hemodynamic shock, or cardiac arrest. Highly effective but carrying a significant risk of serious bleeding, thrombolytics require careful patient selection.
• Catheter-directed therapies. When systemic thrombolysis is contraindicated, a catheter can be advanced directly into the pulmonary artery to deliver thrombolytics locally at lower doses, or to mechanically fragment the clot. These techniques carry a lower bleeding risk than systemic thrombolysis and are suited to specific patient groups.
• Surgical embolectomy. In massive pulmonary embolism unresponsive to medical treatment, or when thrombolysis is contraindicated, the clot can be surgically removed via open-heart surgery. A high-risk procedure, it can be life-saving when no other option is available.
• Inferior vena cava filter. A device implanted in the inferior vena cava to mechanically prevent new clots from reaching the lungs. It is considered when anticoagulation is contraindicated or when embolism recurs despite adequate anticoagulation. Due to long-term complications, it is used selectively.
• Oxygen support and intensive care. Supplemental oxygen is provided for all hypoxic patients; ventilatory support may be needed in severe cases. Hemodynamic instability — hypotension and shock — requires vasoactive medications and intensive care monitoring.
• Long-term treatment and secondary prevention. Continued anticoagulation after the acute episode substantially reduces recurrence risk. Treatment duration is determined by the triggering cause, presence of thrombophilia, and bleeding risk. Active cancer, hereditary thrombophilia, and a history of recurrent thrombosis may all necessitate lifelong anticoagulation.

Complications

With timely and appropriate treatment, most patients with pulmonary embolism recover fully. However, delayed or inadequate treatment can lead to serious and lasting complications.

• Sudden death. The most feared outcome of massive pulmonary embolism. Abrupt obstruction of the main pulmonary arteries can cause acute right heart failure and cardiac arrest. The speed of treatment initiation is the primary determinant of this risk.
• Chronic thromboembolic pulmonary hypertension (CTEPH). When a clot does not dissolve completely, the residual obstruction causes permanent scarring and elevated pressure in the pulmonary arteries. This manifests as progressive breathlessness, exercise intolerance, and eventually right heart failure. Surgical pulmonary endarterectomy at specialized centers offers a curative option for selected patients.
• Pulmonary infarction. Death of lung tissue in the territory deprived of blood flow. It typically presents with pleuritic chest pain, hemoptysis, and low-grade fever, and usually resolves over time, though permanent scarring can remain in severe cases.
• Right heart failure. Massive pulmonary embolism imposes an acute and severe pressure overload on the right ventricle. Acute right heart failure dramatically increases early mortality and can predispose to chronic right-sided cardiac dysfunction in the longer term.
• Paradoxical embolism and stroke. In patients with a patent foramen ovale — a congenital opening in the heart — the elevated right-sided pressures of pulmonary embolism can force clot through this opening into the left heart and then to the brain, causing ischemic stroke.
• Recurrent venous thromboembolism. Inadequate treatment or persistence of the underlying risk factor increases the likelihood of both recurrent deep vein thrombosis and further pulmonary embolism. Each new event compounds the cumulative burden of injury.
• Bleeding complications. The unavoidable trade-off of anticoagulant therapy is an increased bleeding risk. Gastrointestinal bleeding, intracranial hemorrhage, and other serious bleeding events can occur. This risk is managed through careful dosing and regular monitoring.

Living After Pulmonary Embolism

Experiencing a pulmonary embolism is a physically and emotionally demanding event. With appropriate treatment and careful follow-up, the great majority of patients recover well and return to a full and active life.

Adhering to Anticoagulation

Take your blood-thinning medication for the full duration prescribed. Never stop independently — this decision always belongs to your doctor. If you are on warfarin, regular INR monitoring is essential. Newer oral anticoagulants such as rivaroxaban and apixaban do not require routine monitoring but must be taken consistently. Always inform any healthcare provider — including dentists — that you are on anticoagulant therapy before any procedure.

Recognizing Bleeding Signs

While on anticoagulants, learn to recognize signs of abnormal bleeding. Blood in the urine or stool, unexplained bruising, prolonged nosebleeds, bleeding gums, and severe or sudden headache all warrant prompt medical contact.

Physical Activity

Early mobilization after pulmonary embolism is encouraged — prolonged bed rest promotes new clot formation. Gradually increase activity as breathlessness improves. Before returning to high-intensity exercise, seek explicit clearance from your doctor. For patients who develop chronic thromboembolic pulmonary hypertension, exercise capacity and programming should be individually designed.

Long Journeys and Prolonged Sitting

On long flights or journeys, drink plenty of water, wear compression stockings, and get up to walk regularly. Your doctor may recommend a low molecular weight heparin injection before long travel. If you work at a desk, take a brief walk every hour.

Hormonal Medications and Pregnancy

Do not switch to estrogen-containing contraception after a pulmonary embolism without discussing it with your doctor first. If pregnancy is being planned, anticoagulation management requires a specific strategy — consult a hematologist or obstetric medicine specialist before conceiving.

Regular Follow-up

The first follow-up appointment is typically scheduled within a few weeks of discharge. Continue attending all monitoring appointments throughout and beyond the anticoagulation period. Breathlessness that fails to improve or worsens over time may indicate the development of chronic complications and requires further evaluation.

Preparing for Your Appointment

Whether attending an emergency department or a follow-up appointment, being prepared helps your medical team work efficiently and make well-informed decisions.

What you can do:

• Note when symptoms began, what they feel like, and how they have evolved
• Mention any recent surgery, long journey, or period of extended immobility
• List all current medications, particularly contraceptives and blood thinners
• Report any family history of thrombosis, deep vein thrombosis, or pulmonary embolism in younger relatives
• Mention any coexisting conditions such as cancer, pregnancy, or heart disease
• Write your questions down in advance

Questions you may wish to ask your doctor:

• How large is the embolism and how serious is my situation?
• Which medication will I receive and for how long?
• Will I be tested for an underlying clotting disorder?
• What can I do to reduce my risk of a recurrence?
• When can I return to normal activities and to work?
• Are there restrictions on travel or exercise?
• What signs of bleeding should prompt me to seek urgent care?
• How often should I come for follow-up?

Questions your doctor may ask:

• When did the breathlessness start and how has it progressed?
• Do you have chest pain, and does it change with breathing?
• Have you noticed swelling, pain, or redness in either leg?
• Have you had surgery recently or been immobile for a prolonged period?
• Are you receiving cancer treatment?
• Are you pregnant or taking an oral contraceptive?
• Is there a family history of blood clots?
• Have you ever had a deep vein thrombosis or pulmonary embolism before?
• What medications are you currently taking?